1991
DOI: 10.1016/0014-2999(91)90536-y
|View full text |Cite
|
Sign up to set email alerts
|

Structure-activity relationships of the δ-opioid-selective agonists, deltorphins

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
52
0
1

Year Published

1993
1993
2021
2021

Publication Types

Select...
6
3

Relationship

2
7

Authors

Journals

citations
Cited by 72 publications
(60 citation statements)
references
References 15 publications
7
52
0
1
Order By: Relevance
“…The specificity of dermorphin-saporin for RVM cells expressing -opioid receptors was confirmed by the use of ␤-FNA, a selective and irreversible -opioid receptor antagonist (Ward et al, 1982;Jiang et al, 1990). RVM microinjection of ␤-FNA was shown to antagonize the antinociceptive effects of a receptor-selective opioid , but not selective ␦ or , agonist indicating that the dose administered selectively blocked -opioid receptors; the selectivity of the antagonist is supported by similar results in previous studies (Tiberi et al, 1988;Melchiorri et al, 1991). Administration of RVM dermorphin-saporin in rats pretreated with ␤-FNA showed that the expected prevention of nerve injury-induced pain was blocked; ␤-FNA pretreatment did not alter the development of nerve injury-induced pain in groups pretreated with either dermorphin or saporin.…”
Section: Discussionsupporting
confidence: 71%
“…The specificity of dermorphin-saporin for RVM cells expressing -opioid receptors was confirmed by the use of ␤-FNA, a selective and irreversible -opioid receptor antagonist (Ward et al, 1982;Jiang et al, 1990). RVM microinjection of ␤-FNA was shown to antagonize the antinociceptive effects of a receptor-selective opioid , but not selective ␦ or , agonist indicating that the dose administered selectively blocked -opioid receptors; the selectivity of the antagonist is supported by similar results in previous studies (Tiberi et al, 1988;Melchiorri et al, 1991). Administration of RVM dermorphin-saporin in rats pretreated with ␤-FNA showed that the expected prevention of nerve injury-induced pain was blocked; ␤-FNA pretreatment did not alter the development of nerve injury-induced pain in groups pretreated with either dermorphin or saporin.…”
Section: Discussionsupporting
confidence: 71%
“…The IC 50 values obtained in preparations from wild-type mice were 13.89 Ϯ 2.16 nM for DPDPE and 1.87 Ϯ 0.30 nM for deltorphin II. A similar activity profile of the two agonists was reported previously in Albino Swiss mice (Melchiorri et al, 1991), although vas deferens preparations from this mouse strain were more responsive to ␦-opioid agonists than those from hybrid 129/SV x C57Bl/6 mice used in the present study. In mutant mice, IC 50 values were 22.44 Ϯ 4.59 nM for DPDPE and 3.85 Ϯ 0.90 nM for deltorphin II.…”
Section: Inhibition Of the Vas Deferens Twitch In Mor-deficient Micesupporting
confidence: 66%
“…Provided that the &receptor selectivity of deltorphin-I1 is primarily based on the molecular conformations of this peptide and not on other factors such as hydrophobicity or hydrophilicity, it may be that the turn conformation of the C-terminal tripeptide, which is detached from the helically folded conformation of the N-terminal tetrapeptide, plays an important role in discriminating the @&selectivity, because the N-terminal peptide of p-selective dermorphin (Tyr-D-AlaPhe-Gly-Tyr-Pro-Ser-NH,) has been reported to take a similar folded conformation [22]. Similar conclusions have also been reached by other groups [15, 20,34,[36][37][38]. This suggests that the message-address concept proposed by Schwyzer [39] is a useful approach for understanding the structuralkonformational characteristics of the receptorselective opioid [40,411 in such a way that the opioid is recognized by a message subsite of the receptor and its selectivity is dominated by interaction with the address subsite.…”
Section: Conformational Relationship With P/d-selectivitysupporting
confidence: 73%